Patient‐reported outcomes (PROs) in Waldenström macroglobulinemia (WM) patients treated with ibrutinib‐rituximab in the iNNOVATE study Meeting Abstract
| Authors: | Tedeschi, A.; Dimopoulos, M. A.; Trotman, J.; García‐Sanz, R.; Macdonald, D.; Mahe, B.; Herbaux, C.; Heffner, L. T.; Tam, C. S.; Varettoni, M.; Palomba, M. L.; Matous, J. V.; Shustik, C.; Kastritis, E.; Treon, S. P.; Li, J.; Poulsen, E. G.; Hauns, B.; Buske, C.; Leblond, V. |
| Abstract Title: | Patient‐reported outcomes (PROs) in Waldenström macroglobulinemia (WM) patients treated with ibrutinib‐rituximab in the iNNOVATE study |
| Meeting Title: | 15th International Conference on Malignant Lymphoma |
| Journal Title: | Hematological Oncology |
| Volume: | 37 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2019 Jun 18-22 |
| Meeting Location: | Lugano, Switzerland |
| ISSN: | 0278-0232 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2019-06-01 |
| Start Page: | 235 |
| End Page: | 237 |
| Language: | English |
| ACCESSION: | 137029388 |
| DOI: | 10.1002/hon.47_2630 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cin20 |
| PUBMED: | 31187525 |
| DOI/URL: | |
| Notes: | Meeting Abstract: 183 -- Source: cin20 |
